Skip to main
MMED

MMED Stock Forecast & Price Target

MMED Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 56%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Minimed Group Inc is projected to experience EBITDA margin expansion from approximately 16% today to the mid-20s over the next few years, supported by sustained high single-digit sales growth. The company boasts a robust balance sheet and durable margins, positioning it favorably for continued growth within the expanding market for advanced diabetes technology. Additionally, the International segment's consistent double-digit sales growth, coupled with new product launches like MiniMed Go and the Instinct CGM sensor, is expected to further drive revenue growth in the future.

Bears say

Minimed Group Inc. is facing a negative financial outlook primarily due to anticipated declines in key metrics, including negative earnings per share (EPS) as new products are launched, with recovery projected only in the long term. Regulatory risks are significantly impacting the company's ability to bring devices and algorithms to market, evidenced by a past FDA warning letter that has contributed to delays in product approvals and a competitive disadvantage in the diabetes management market. Furthermore, penetration rates for Minimed’s products remain notably low among Type 1 and Type 2 insulin-dependent patients in both developed and emerging markets, combined with a historical struggle to meet product development timelines that may hinder the company's competitive position.

MMED has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 56% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiniMed Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiniMed Group Inc (MMED) Forecast

Analysts have given MMED a Buy based on their latest research and market trends.

According to 9 analysts, MMED has a Buy consensus rating as of Apr 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiniMed Group Inc (MMED)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.